{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:24:28Z","timestamp":1793165068421,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biopha.2021.112357","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T05:09:59Z","timestamp":1635397799000},"page":"112357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids"],"prefix":"10.1016","volume":"144","author":[{"given":"Soumalya","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedha","family":"Mukhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Kamboj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedula","family":"Sasibhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiva Kumar","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sastry Lakshminarayana","family":"Jatavallabhula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashwant","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Dikshit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112357_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118404","article-title":"Hypoxia aggravates non-alcoholic fatty liver disease in presence of high fat choline deficient diet: a pilot study","volume":"260","author":"Sarkar","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2021.112357_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","article-title":"Current status of imaging in nonalcoholic fatty liver disease","volume":"10","author":"Li","year":"2018","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.biopha.2021.112357_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2021.112357_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2021.112357_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.653872","article-title":"Methanolic extract of Lysimachia Candida Lindl. prevents high-fat high-fructose-induced fatty liver in rats: understanding the molecular mechanism through untargeted metabolomics study","volume":"12","author":"Kamboj","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2021.112357_bib6","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2021.112357_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"10.1016\/j.biopha.2021.112357_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrendo.2017.42","article-title":"Endocrine-disrupting chemicals and fatty liver disease","volume":"13","author":"Foulds","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2021.112357_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/children4060046","article-title":"The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease","volume":"4","author":"Perla","year":"2017","journal-title":"Children"},{"key":"10.1016\/j.biopha.2021.112357_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.numecd.2008.12.015","article-title":"Hepatic lipid metabolism and non-alcoholic fatty liver disease","volume":"19","author":"Tessari","year":"2009","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.biopha.2021.112357_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40519-018-0481-6","article-title":"Insulin resistance in obesity: an overview of fundamental alterations","volume":"23","author":"Barazzoni","year":"2018","journal-title":"Eat Weight Disord."},{"issue":"Suppl 2","key":"10.1016\/j.biopha.2021.112357_bib12","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1055\/s-2001-18576","article-title":"Insulin resistance: definition and consequences","volume":"109","author":"Lebovitz","year":"2001","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.biopha.2021.112357_bib13","unstructured":"A.M. Freeman, N. Pennings, Insulin Resistance, StatPearls, Treasure Island (FL), 2021."},{"key":"10.1016\/j.biopha.2021.112357_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPARalpha\/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.biopha.2021.112357_bib15","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.112357_bib16","unstructured":"C. Market, Zydus receives DCGI approval of Saroglitazar Mg for treatment of Non-Alcoholic Fatty Liver Disease in India, 2020. \u3008https:\/\/www.business-standard.com\/article\/news-cm\/zydus-receives-dcgi-approval-of-Saroglitazar-mg-for-treatment-of-non-alcoholic-fatty-liver-disease-in-india-120123000275_1.html\u3009. (Accessed 26 July 2021)."},{"key":"10.1016\/j.biopha.2021.112357_bib17","unstructured":"Z. Cadila, Zydus receives approval from DCGI for Saroglitazar Magnesium for treatment of Type II Diabetes 2020. \u3008https:\/\/www.zyduscadila.com\/public\/pdf\/pressrelease\/Zydus_SaroglitazarMg_Diabetes_approval.pdf\u3009. (Accessed 26 July 2021)."},{"key":"10.1016\/j.biopha.2021.112357_bib18","unstructured":"Dabur, Dabur Hepano. \u3008https:\/\/www.dabur.com\/in\/en-us\/ayurvedic-herbal-products\/dabur-Hepano\u3009. (Accessed 26 July 2021)."},{"key":"10.1016\/j.biopha.2021.112357_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/ddt.DDT_12_16","article-title":"Efficacy and safety of hepano tablet in liver disorder patients with abnormal liver function test: a randomized active controlled prospective clinical study","volume":"8","author":"Kumar","year":"2017","journal-title":"Drug Dev. Ther."},{"key":"10.1016\/j.biopha.2021.112357_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010360","article-title":"Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL\/6 mice model via AMPK\/Sirt1\/SREBP-1c\/PPARgamma pathway","volume":"21","author":"Chyau","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112357_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cimb43010003","article-title":"Effect of Bombyx mori on the liver protection of non-alcoholic fatty liver disease based on in vitro and in vivo models","volume":"43","author":"Park","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.biopha.2021.112357_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900109","article-title":"Vitamin D deficiency in rats causes cardiac dysfunction by inducing myocardial insulin resistance","volume":"63","author":"Nizami","year":"2019","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.biopha.2021.112357_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/0471142735.ima03bs111","article-title":"Trypan blue exclusion test of cell viability","volume":"111","author":"Strober","year":"2015","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.biopha.2021.112357_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1210\/endo.142.1.7863","article-title":"Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1","volume":"142","author":"Cousin","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2021.112357_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0022-1759(90)90187-Z","article-title":"MTT colorimetric assay for testing macrophage cytotoxic activity in vitro","volume":"131","author":"Ferrari","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.biopha.2021.112357_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1039\/C8AN01219A","article-title":"Merging metabolomics and lipidomics into one analytical run","volume":"144","author":"Schwaiger","year":"2018","journal-title":"Analyst"},{"key":"10.1016\/j.biopha.2021.112357_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12859-017-1744-3","article-title":"LipidMatch: an automated workflow for rule-based lipid identification using untargeted high-resolution tandem mass spectrometry data","volume":"18","author":"Koelmel","year":"2017","journal-title":"BMC Bioinform."},{"key":"10.1016\/j.biopha.2021.112357_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2021.112357_bib29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPARalpha\/gamma agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2021.112357_bib30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2021.112357_bib31","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR alpha\/gamma agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.112357_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.metabol.2012.06.008","article-title":"High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice","volume":"62","author":"Tsuchiya","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2021.112357_bib33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.carbpol.2018.07.086","article-title":"Polysaccharides extracted from Phellinus linteus ameliorate high-fat high-fructose diet induced insulin resistance in mice","volume":"200","author":"Feng","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.biopha.2021.112357_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146675","article-title":"Effects of excess energy intake on glucose and lipid metabolism in C57BL\/6 mice","volume":"11","author":"Pang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2021.112357_bib35","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/hep.22239","article-title":"Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways","volume":"47","author":"Wu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2021.112357_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/nu10060735","article-title":"Hepatoprotective effects of insect extracts in an animal model of nonalcoholic fatty liver disease","volume":"10","author":"Im","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2021.112357_bib37","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0022-3565(25)22984-6","article-title":"Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice","volume":"255","author":"Fromenty","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2021.112357_bib38","first-page":"75","article-title":"Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives","volume":"4","author":"Ramachandran","year":"2018","journal-title":"J. Clin. Transl. Res."},{"key":"10.1016\/j.biopha.2021.112357_bib39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3389\/fendo.2018.00384","article-title":"Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes","volume":"9","author":"Oh","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2021.112357_bib40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41580-018-0044-8","article-title":"Metabolites as regulators of insulin sensitivity and metabolism","volume":"19","author":"Yang","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2021.112357_bib41","article-title":"Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia","volume":"7","author":"Maev","year":"2020","journal-title":"BMJ Open Gastroenterol."},{"key":"10.1016\/j.biopha.2021.112357_bib42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.nut.2004.11.019","article-title":"Dietary phosphatidylcholine alleviates fatty liver induced by orotic acid","volume":"21","author":"Buang","year":"2005","journal-title":"Nutrition"},{"key":"10.1016\/j.biopha.2021.112357_bib43","article-title":"Aspects of transition cow metabolomics-Part I: effects of a metaphylactic butaphosphan and cyanocobalamin treatment on the metabolome in liver, blood, and urine in cows with different liver metabotypes","author":"Scharen","year":"2021","journal-title":"J. Dairy Sci."},{"key":"10.1016\/j.biopha.2021.112357_bib44","doi-asserted-by":"crossref","first-page":"9648","DOI":"10.1038\/s41598-019-46185-w","article-title":"Activation of the phosphatidylcholine to lysophosphatidylcholine pathway is associated with osteoarthritis knee cartilage volume loss over time","volume":"9","author":"Zhai","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.112357_bib45","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.3390\/ijms22105375","article-title":"Nonalcoholic fatty liver disease (NAFLD). Mitochondria as players and targets of therapies?","volume":"22","author":"Di Ciaula","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112357_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1042\/bst0320147","article-title":"Plasmalogens: targets for oxidants and major lipophilic antioxidants","volume":"32","author":"Engelmann","year":"2004","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.biopha.2021.112357_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0531-5565(98)00014-X","article-title":"The biological significance of plasmalogens in defense against oxidative damage","volume":"33","author":"Brosche","year":"1998","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.biopha.2021.112357_bib48","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/hep.24782","article-title":"Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice","volume":"55","author":"Ling","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2021.112357_bib49","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1139\/apnm-2012-0261","article-title":"Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine","volume":"38","author":"Arendt","year":"2013","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"10.1016\/j.biopha.2021.112357_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218067","article-title":"The emerging and diverse roles of bis(monoacylglycero) phosphate lipids in cellular physiology and disease","volume":"21","author":"Showalter","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112357_bib51","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1021\/jf703578d","article-title":"Dietary phosphatidylinositol prevents the development of nonalcoholic fatty liver disease in Zucker (fa\/fa) rats","volume":"56","author":"Shirouchi","year":"2008","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.biopha.2021.112357_bib52","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fendo.2019.00577","article-title":"The role of ceramides in insulin resistance","volume":"10","author":"Sokolowska","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2021.112357_bib53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/egh.09.32","article-title":"Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal","volume":"3","author":"Alkhouri","year":"2009","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2021.112357_bib54","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1073\/pnas.1804266115","article-title":"Traceless synthesis of ceramides in living cells reveals saturation-dependent apoptotic effects","volume":"115","author":"Rudd","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2021.112357_bib55","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1515\/jpem-2012-0407","article-title":"Plasma ceramides are elevated in female children and adolescents with type 2 diabetes","volume":"26","author":"Lopez","year":"2013","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2021.112357_bib56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fendo.2019.00665","article-title":"Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease","volume":"10","author":"Jiang","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2021.112357_bib57","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cmet.2014.10.017","article-title":"C16:0-ceramide signals insulin resistance","volume":"20","author":"Hla","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2021.112357_bib58","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cmet.2014.08.002","article-title":"Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance","volume":"20","author":"Turpin","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2021.112357_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.plipres.2005.11.002","article-title":"Ceramides in insulin resistance and lipotoxicity","volume":"45","author":"Summers","year":"2006","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.biopha.2021.112357_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010040","article-title":"Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover","volume":"21","author":"Simon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.112357_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biochi.2018.07.021","article-title":"Sphingolipid metabolism in non-alcoholic fatty liver diseases","volume":"159","author":"Regnier","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2021.112357_bib62","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cell.2019.04.010","article-title":"Deficient endoplasmic reticulum-mitochondrial phosphatidylserine transfer causes liver disease","volume":"177","author":"Hernandez-Alvarez","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2021.112357_bib63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12986-018-0288-5","article-title":"Changes in lysophospholipids and liver status after weight loss: the RESMENA study","volume":"15","author":"Cantero","year":"2018","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.biopha.2021.112357_bib64","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/eci.12486","article-title":"Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD","volume":"45","author":"Pathil","year":"2015","journal-title":"Eur. J. Clin. Investig."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:48:56Z","timestamp":1760100536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221011410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":64,"alternative-id":["S0753332221011410"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112357","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112357"}}